Comment on: 'Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada', Wilson et al., 22 June 2018.

McGirr, Ashleigh; Iqbal, Shehzad M; Olbrecht, Jan; Varghese, Lijoy

McGirr, Ashleigh; Iqbal, Shehzad M; Olbrecht, Jan; Varghese, Lijoy.

McGirr A; GSK, Mississauga, ON, Canada. ashleigh.a.mcgirr@gsk.com.
Iqbal SM; GSK, Mississauga, ON, Canada.
Olbrecht J; GSK, Wavre, Belgium.
Varghese L; GSK, Singapore, Singapore.

Infect Dis Ther ; 7(4): 535-538, 2018 Dec.

Article en En | MEDLINE | ID: mdl-30411202

Palabras clave

Canada; Cost-effectiveness; Invasive pneumococcal disease; PCV-13; PHiD-CV; Pneumococcal conjugate vaccines

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Health_economic_evaluation Idioma: En Año: 2018 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Health_economic_evaluation Idioma: En Año: 2018 Tipo del documento: Article